New data from the TARGET trial, the first randomized trial to assess on-site machine learning-based CT-FFR strategy in CAD management.
- Clinical Validation of DEEPVESSEL® FFR: AI CT-FFR Analysis by Keya Medical
- TARGET Randomized On-Site CT FFR Trial Results
- Keya Medical’s CT FFR analysis DEEPVESSEL® is now available in the USA.
- The future of AI-driven, noninvasive CT FFR technology-DeepVessel FFR at 2022 cardiology events in China
- DEEPVESSEL FFR, Keya Medical Deep-Learning Based, Non-Invasive Coronary Artery Functional Assessment Software Device, Receives FDA Clearance.